Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050388 · ClinicalTrials.gov registry record · Phase 3
Phase II Trial of Allovectin-7® for Head and Neck Cancer
A Phase 3 study, sponsored by Vical.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00050388: Completed Phase 3 study, sponsored by Vical.
NCT00050388 is a Phase 3 study that has completed, run by Vical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050388, a Phase 3 study, has completed, sponsored by Vical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.
Interventions
- GENETIC Allovectin-7®
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2002-06 |
| Phase | Phase 3 |
What the finished NCT00050388 record still lists
NCT00050388 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Allovectin-7® is the first listed.
NCT00050388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050388 about?
NCT00050388 is a clinical study titled "Phase II Trial of Allovectin-7® for Head and Neck Cancer". The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.
What is the current status of trial NCT00050388?
This trial is currently completed. It is a Phase 3 study. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00050388?
The interventions under investigation include: Allovectin-7® (GENETIC).
Who is sponsoring clinical trial NCT00050388?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.